InflaRx NV (IFRX)
2.22
-0.01
(-0.45%)
USD |
NASDAQ |
Sep 04, 16:00
2.22
0.00 (0.00%)
After-Hours: 20:00
InflaRx Research and Development Expense (Quarterly) : 5.510M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.510M |
| March 31, 2026 | 4.411M |
| September 30, 2025 | 7.293M |
| June 30, 2025 | 8.164M |
| March 31, 2025 | 7.384M |
| September 30, 2024 | 12.24M |
| June 30, 2024 | 10.78M |
| March 31, 2024 | 7.925M |
| December 31, 2023 | 8.676M |
| September 30, 2023 | 7.947M |
| June 30, 2023 | 11.88M |
| March 31, 2023 | 15.81M |
| December 31, 2022 | 8.503M |
| September 30, 2022 | 7.588M |
| June 30, 2022 | 11.90M |
| March 31, 2022 | 11.75M |
| December 31, 2021 | 11.58M |
| September 30, 2021 | 11.03M |
| June 30, 2021 | 13.62M |
| March 31, 2021 | 5.910M |
| Date | Value |
|---|---|
| December 31, 2020 | 6.894M |
| September 30, 2020 | 6.132M |
| June 30, 2020 | 8.101M |
| March 31, 2020 | 8.041M |
| December 31, 2019 | 11.96M |
| September 30, 2019 | 14.71M |
| June 30, 2019 | 13.83M |
| March 31, 2019 | 8.605M |
| December 31, 2018 | 10.27M |
| September 30, 2018 | 6.277M |
| June 30, 2018 | 5.958M |
| March 31, 2018 | 6.700M |
| December 31, 2017 | 7.426M |
| September 30, 2017 | 3.061M |
| June 30, 2017 | 3.415M |
| March 31, 2017 | 2.559M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 0.647M |
| March 31, 2016 | 0.9305M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| MediGene AG | -- |
| BioNTech SE | 514.38M |
| Immatics NV | 72.57M |
| Beam Therapeutics, Inc. | 95.10M |
| Kymera Therapeutics, Inc. | 117.45M |